B7-1 antigen expression in tumor cells from cancerous human tissues

Analytical and Quantitative Cytology and Histology

Volumn 21, Issue 6, 1999, Pages 521-526

  Si, Lusheng ^a   Si, Huaxin ^a   Chen, Yunying ^a   Sun, Yi ^a   Wang, Yili ^a  

^a XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

B7 antigen; Cancer; Neoplasms; Tumors

Indexed keywords

B7 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; DENDRITIC CELL; HUMAN; HUMAN TISSUE; INTERSTITIUM; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

ADENOCARCINOMA; ANTIGENS, CD80; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEIOMYOMA; LUNG NEOPLASMS; NEOPLASMS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0033404818     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Liu Y, Linsley PS: Costimulation of T-cell growth. Curr Opin Immunol 1992;4:265-276
2. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068
3. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S: The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990;144:4579-4586
4. Damle NK, Klussman K, Aruffo A: ICAM-2, a second ligand for CD11a/CD18 (LFA-1), provides a costimulatory signal for T cell receptor-initiated actiation of human T cells. J Immunol 1992;148:665-674
5. Bierer BE, Peterson A, Gorga GC, Herrmann SH, Burakoff SJ: Synergistic T cell activation via the physiological ligand for CD2 and the T cell receptor. J Exp Med 1988;168:1145-1156
6. Damle NK, Aruffo A: Vascular cell adhesion molecule-1 induces T cell antigen receptor-dependent activation of human CD4+ T lymphocytes. Proc Natl Acad Sci USA 1991;88:6403-6409
7. Damle NK, Klussma K, Linsley PS, Aruffo A: Diffrential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4′ T lymphocytes. J Immunol 1992;148:1985-1992
8. Nickoloff BJ, Turka LA: Immunological functions of non-professional antigen-presenting cells: New insights from studies of T-cell interactions with keratinocytes. Immunol Today 1994;15:464-469
9. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gar G, Nadler LM: Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Immunology 1993;90:11059-11063
10. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-795
11. Fraser JD, Irving BA, Crabtree GR, Weiss A: Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-316
12. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, MoGowan P, and Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71: 1093-1102
13. Townsend SE, Allison JP: Tumor rejection after direct co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:268-370
14. Freeman GJ Freedman AS, Segil JM, LeeG, Whitman JF, Nadler LM: B7: A new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989;143:2714-2722
15. Murray PG, Oates J, Regnoid GM, Crocher J, Young LS: Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection. Clin Pathol 1995;48:101-108
16. Denfeld RW, Dietrich A, Wuttig C, Tanczes E, Weiss JM, Vanscheidt W, Schopf E, Simon JC: In situ expression of B7 and CD28 receptor families in human malignant melanoma relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 1995;62:259-265
17. Nickoloff BJ, Mitra RS, Lee K, Turka LA, Green J, Thompson C, Shimizu Y: Discordant expression of CD28 ligands. BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 1993;142:1029-1040
18. Chen LP, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-532
19. Azuma M, Cayabyad M, Phillips JH, Lanier LL: Requirements for CD28-dependent T cell mediated cytotoxicity. J Immunol 1993;150:2091-2101
20. Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin V, Hombach A, VanLier R, Schwonzen M, Diehl V: CD30-antigen-specific targeting and activation of T cells via murine biospecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma. Int J Cancer 1993;54:820-827
21. Pardoll DM: Cancer vaccines. Immunol Today 1993;14: 310-316
22. + effectors from tumor-infiltrating lymphocytes. Cancer Res 1989;49:5979-5985
23. Ikeda H, Sato N, Matsuura A: Analysis of T-cell receptor V region gene usage of cytotoxic T lymphocytes and tumor-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas. Cancer Res 1993;53: 3078-3084
24. Bakker ABH, Schreurs MWJ, De Boer AJ: Melanocyte line-age-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-1009
25. Currie G: Cancer and the Immune Response. Second edition, second volume. Edited by JL Turk. Edward Arnold, 1980, pp 4-13